Research location
Düsseldorf
North Rhine-Westphalia, Germany
Advertisement
Research activity in Düsseldorf
North Rhine-Westphalia, GermanyCureCurrent currently publishes aggregate city-level research activity for this location: 164 trials and 179 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Düsseldorf
164 linked trials · page 1 of 4Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCNCT07242352 · 2026-04-29 · 1 site observation
RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)NCT07282574 · 2026-03-10 · 1 site observation
RECRUITING
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced CancersNCT07227298 · 2026-01-30 · 1 site observation
RECRUITING
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767 · 2025-11-03 · 1 site observation
RECRUITING
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)NCT07206056 · 2025-10-15 · 1 site observation
RECRUITING
Impella Pump Return Study to Analyze Deposits and Biomaterial in Used PumpsNCT06765226 · 2025-09-21 · 1 site observation
RECRUITING
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)NCT06926868 · 2025-09-11 · 1 site observation
RECRUITING
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune DiseasesNCT07115745 · 2025-09-04 · 1 site observation
RECRUITING
Biological Determinants and Neural Compensation of Dysphagia in Parkinson's DiseaseNCT07299448 · 2025-09-01 · 1 site observation
RECRUITING
METABolic Deterioration in HTX Determines OutcomesNCT07372820 · 2025-07-24 · 1 site observation
RECRUITING
AI-based pCR Assessment/Prediction in HER2-Positive BC Using PET/MRINCT06708910 · 2025-07-18 · 1 site observation
RECRUITING
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)NCT06841354 · 2025-03-16 · 1 site observation
RECRUITING
A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceNCT06830720 · 2025-02-20 · 3 site observations
RECRUITING
Impact of [18F] PSMA-1007 Imaging for Primary Staging of Prostate CancerNCT06820333 · 2025-01-10 · 1 site observation
RECRUITING
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerNCT06201234 · 2024-12-13 · 2 site observations
RECRUITING
Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate CancerNCT06657131 · 2024-11-01 · 1 site observation
RECRUITING
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)NCT06081244 · 2024-10-10 · 2 site observations
RECRUITING
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27 · 1 site observation
RECRUITING
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)NCT06469944 · 2024-09-20 · 1 site observation
RECRUITING
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's DiseaseNCT06565195 · 2024-08-27 · 1 site observation
RECRUITING
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)NCT06445972 · 2024-08-07 · 1 site observation
RECRUITING
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)NCT06393374 · 2024-06-24 · 1 site observation
RECRUITING
Measuring Silent Disease Progression in Multiple Sclerosis With a Multimodal ApproachNCT06501950 · 2024-06-20 · 1 site observation
RECRUITING
Determination of Prostate-specific Antigen in Capillary Blood (PSA-Cap)NCT06626386 · 2024-06-01 · 1 site observation
RECRUITING
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)NCT06312176 · 2024-04-14 · 1 site observation
RECRUITING
Phase IIIb Study of Ribociclib + ET in Early Breast CancerNCT05827081 · 2024-02-28 · 1 site observation
RECRUITING
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerNCT05704829 · 2024-02-05 · 2 site observations
RECRUITING
PROCARE - PROstate Cancer Real World Evidence RegistryNCT06835218 · 2024-01-29 · 1 site observation
RECRUITING
Smart Monitoring Assessing Spasticity-related HealthNCT06937723 · 2023-10-19 · 1 site observation
RECRUITING
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)NCT05319730 · 2023-05-16 · 1 site observation
RECRUITING
Home-based Gait and Balance Training in Patients With Movement DisordersNCT06617884 · 2023-01-04 · 1 site observation
RECRUITING
PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFSNCT05792150 · 2022-12-07 · 2 site observations
RECRUITING
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple SclerosisNCT05344469 · 2022-05-10 · 1 site observation
RECRUITING
Abbott DBS Post-Market Study of Outcomes for Indications Over TimeNCT04071847 · 2019-11-26 · 1 site observation
RECRUITING
Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMINCT05046483 · 2018-12-30 · 1 site observation
RECRUITING
Praegnant Breast Cancer: Early/Advanced/MetastaticNCT02338167 · 2014-06-01 · 1 site observation
RECRUITING
The Effect of Bariatric Surgery on Insulin Sensitivity and Energy MetabolismNCT01477957 · 2012-09-01 · 1 site observation
RECRUITING
Study on Pancreatic Islets in Patients Undergoing (Partial) Pancreatectomy (PRECISE)NCT06150690 · 2012-08-21 · 1 site observation
RECRUITING
Prospective Study on Diabetes Mellitus and Its Complications in Newly Diagnosed Adult PatientsNCT01055093 · 2005-09-01 · 1 site observation
RECRUITING
Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac AmyloidosisNCT07577466 · 2026-06-15 · 1 site observation
NOT_YET_RECRUITING
RELIEVE METAB StudyNCT07555925 · 2026-06-01 · 1 site observation
NOT_YET_RECRUITING
A Study Testing Whether Low-Dose Radiation Could Help the Immune System and Possibly Improve Early-Onset Alzheimer's Disease.NCT07564700 · 2026-05-15 · 1 site observation
NOT_YET_RECRUITING
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)NCT06991556 · 2025-07-07 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1NCT06694805 · 2024-12-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Influence of Electronic Patient Reported Outcomes (ePROMs) in Surgical Therapy for Prostate Cancer on Postoperative OutcomeNCT05644821 · 2023-08-01 · 1 site observation
COMPLETED
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)NCT05798520 · 2023-07-25 · 1 site observation
COMPLETED
Computer-assisted Risk Evaluation in the Early Detection of Psychotic DisordersNCT05813080 · 2023-05-01 · 1 site observation
COMPLETED
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDONCT05033756 · 2022-07-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)NCT05342636 · 2022-07-27 · 1 site observation
COMPLETED
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's DiseaseNCT05310071 · 2022-06-02 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.